SHANGHAI - Zhejiang Jingxin Pharmaceutical Co. Ltd. has acquired a 51% stake in the US contract research organization (CRO) Pharmula Laboratories for $1.02m in cash, marking the first step by the Shanghai-listed manufacturing company to tap into an overseas market for its formulation business.
The purchase of the majority stake in Pharmula indicates the company’s international R&D deployment, Jingxin said in a statement, in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?